TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02959502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Receive tDCS+CR
Description: Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS \&CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facilitate tDCS + CR
Description: Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will be trained to deliver tDCS \&CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.
Study: NCT03368664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab GZ402673
Description: Pharmaceutical form: solution, Route of administration: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Description: Pharmaceutical form: solution, Route of administration: subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-Interferon
Description: Pharmaceutical form: solution, Route of administration: SC / intramuscular (IM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Pharmaceutical form: solution, Route of administration: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Pharmaceutical form: tablet, Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceterizine
Description: Pharmaceutical form: tablet, Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine
Description: Pharmaceutical form: tablet, Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Pharmaceutical form: tablet, Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: Pharmaceutical form: tablet, Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Pharmaceutical form: tablet, Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenydramine
Description: Pharmaceutical form: solution, Route of administration: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other H1 antagonist
Description: Pharmaceutical form: solution, Route of administration: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other H1 antagonist
Description: Pharmaceutical form: tablet/pill, Route of administration: oral
Study: NCT03368807

Intervention type: DEVICE
Intervention: Continuous Glucose Monitoring
Description: Commercially available

Intervention type: DEVICE
Intervention: Continuous Glucose Monitoring
Description: Commercially available

Intervention type: DRUG
Intervention: Insulin Lispro
Description: As prescribed.

Intervention type: DRUG
Intervention: Insulin Lispro
Description: As prescribed.
Study: NCT01035138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semagacestat
Description: 140mg administered orally, once daily for 24 months; dose reduction to 100mg or 60 mg possible due to intolerability
Study: NCT03641976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-FOLFOXIRI
Description: Arm I (A-FOLFOXIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV~Drug: oxaliplatin Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm II (A-FOLFOX/A-FOLFIRI)
Description: Arm II (A-FOLFOX/A-FOLFIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV
Study: NCT01171378

Intervention type: DRUG
Group type: OTHER
Intervention: Ofatumumab
Description: 1000mg vials (50ml @ 20mg/ml), or 100mg vials (5ml @20mg/ml), to be given as an Intravenous (IV) infusion.~Ofatumumab will be infused intravenously on day 1 (300 mg), day 8 (1000 mg) and day 15 (1000mg) in the first cycle, followed by infusions every 3 weeks of 1000 mg on the first day of each cycle for a total of 6 cycles. Maintenance treatment will start 4 weeks after day 1 of cycle 6 in week 20 and consists of six infusions of ofatumumab every 8 weeks
Study: NCT01550133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learned: Non-nutritive beverage to Non-nutritive beverage
Description: For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage product made with non-nutritive sweetener everyday for two weeks.Half of these participants will then be tested against a non-nutritive beverage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learned: Nutritive solid to Nutritive solid
Description: For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive solid.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learned: Nutritive beverage to Nutritive beverage
Description: For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive beverage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Not Learned: Non-nutritive solid to Nutritive solid
Description: For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive solid.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Not Learned: Nutritive beverage to Non-nutritive beverage
Description: For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive beverage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Not Learned: Non-Nutritive solid to Non-nutritive solid
Description: For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive solid.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Not Learned: Non-nutritive beverage to Nutritive beverage
Description: For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive beverage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Not Learned: Non-Nutritive solid to Non-Nutritive Solid
Description: For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive solid.
Study: NCT01990326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XAF5 Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Study: NCT02866656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional conservative treatment
Description: Treatment last for 4 weeks, three times a week,

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional conservative treatment
Description: Treatment last for 4 weeks, three times a week,

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: therapeutic ultrasound
Description: Treatment last for 4 weeks, three times a week, stimulation was given 8 minutes every time, location of treatment were lower limb ischemia area and its surrounding tissues；
Study: NCT00843492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux sodium
Description: After randomization (Day 1), subjects will receive subcutaneously once daily fondaparinux 2.5 mg \[0.5mL\] (1.5 mg \[0.3mL\] in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadroparin
Description: After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
Study: NCT02833896

Intervention type: GENETIC
Intervention: surgery

Intervention type: GENETIC
Intervention: surgery
Study: NCT02683629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTCELL Implantation
Description: NTCELL Implantation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Surgery
Description: Sham Surgery
Study: NCT03651141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic Sliding
Description: Subjects in the neurodynamic sliding group perform 2 movements; 1) movement 1 involves sitting on the edge of the treatment table the bringing their neck to their chest along with bending their knee and pointing their ankle to the ground. Movement 2 is performed by facing their head towards the ceiling and straightening their knee while pointing their ankle towards their nose. Subjects will alternate these 2 active movements for 60s and repeated 5 times, with rest period of 15s between sets. A metronome will be set at 30 beats per minute for 15 full slides per minute to standardize the amount of slides per session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Decompression
Description: For the group receiving the cupping treatment, the subject will lay on their stomach and their affected hamstring will be exposed. Cocoa butter will be applied to the hamstring prior to the application of the cups. 5 cups will be placed along the hamstring and calf muscles. Using a handheld suction pump, each cup will be pumped so that skin fills up half of the cup. The cups will stay in place for five minutes and the clinician will instruct the subject to perform 5 repetitions of active quad sets and 5 repetitions of ankle pumps .

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Diathermy
Description: The control group will receive a sham heat (diathermy treatment). The subjects will be asked to sit and relax for five minutes and the machine will not be turned on with a timer timing the treatment.
Study: NCT00800358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalitol
Description: oral paricalcitol variable daily dosing based on intact PTH level for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: oral calcitriol variable daily dosing based on intact PTH level for 6 months
Study: NCT02343861

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tailored leaflet group
Description: Parents in intervention group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients. In addition to general information, parents in intervention group will also receive the tailored leaflet including the estimated amount of emollients based on the body surface area.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Participants (parents of children with atopic dermatitis) in control group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients.
Study: NCT01583881

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal denervation
Description: Renal denervation
Study: NCT00102323

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 531
Description: Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
Study: NCT03289078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa Treatment
Description: The spa treatments will be realised daily 6 days a week and during 18 days. The care will be provided is : Swimming pool of mobilization by physical therapist (20 minutes daily, Cataplasms (10 minutes daily), Shower in the jet (10 minutes daily), Shower under affusion (10 minutes daily)
Study: NCT01712711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.pylori eradication
Description: The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
Study: NCT01200329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 2775 mg/m2 by vein over about 3 hours on days -8 and -3.
Study: NCT02064348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Solution for s.c. injection or tablets for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Solution for s.c. injection or tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Solution for s.c. injection or tablets for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: Tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: Tablets for oral administration
Study: NCT03277092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VeinViewer®
Description: Near-infrared (NIR) technology consists on light-emitting diodes placed underneath the hand, that makes vessels visible by projecting the processed image in a green light directly on to the puncture site
Study: NCT01200329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient~AUC 4,000 by vein over about 3 hours on days -8 to -5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 60 mg/m2 by vein over about 30 minutes on days -3 and -2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Infusion of stem cells on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: 60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2.
Study: NCT03400449

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video counseling
Description: Video counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conversational counseling
Description: Conversational counseling
Study: NCT03642990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: Capsule
Study: NCT02851602

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood sample
Study: NCT01620645

Intervention type: RADIATION
Intervention: CT scan and PA chest X-ray
Description: All participants will receive a single high resolution CT scan of the chest. This will be performed using a low tube current, helical technique. Participants may also receive a plain chest X-ray if clinically indicated.~The total research protocol dose is 2 mSv. The dose from the chest X-ray is insignificant compared with the dose from the CT scan of the chest, therefore all this dose can be considered to be additional to standard of care. A dose of 2 mSv represents a risk of radiation induced detriment of approximately 1 in 10,000 and is equivalent to about 11 months of average natural background radiation in the UK.
Study: NCT02952651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulse oximeter
Description: When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, POP waveforms are obtained from each index finger, which pulse oximeter sensor is applied by increasing contact force (from 0 to 1.4N, being increased by 0.2-0.3N). Then intravenous crystalloid 10 mL/kg is infused for 15 min.
Study: NCT02499016

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suprapubic single-incision laparoscopic appendectomy
Description: the approach of appendectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suprapubic single-incision laparoscopic appendectomy
Description: the approach of appendectomy
Study: NCT03277092

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The blood drawing is performed traditionally
Study: NCT06064539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Tablet, taken orally
Study: NCT00688441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal CO2
Description: Twice daily during the 14 day Treatment Period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of the study drug dispenser at the same frequency as the active arm
Study: NCT04005040

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile X-ray
Description: Evaluating the effect of mobile x-ray compared to x-ray at the Hospital

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Mobile X-ray
Description: Evaluating the effect of mobile x-ray compared to x-ray at the Hospital
Study: NCT02981979

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leflunomide 10mg Tab
Description: 20mg per day for leflunomide group during the entire study; 20mg per day for control group during the maintenance therapy (start from the 25th week till the end of the study).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide 10mg Tab
Description: 20mg per day for leflunomide group during the entire study; 20mg per day for control group during the maintenance therapy (start from the 25th week till the end of the study).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone Acetate
Description: basic therapy（start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission.）

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone Acetate
Description: basic therapy（start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission.）

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: used in control group during the induced remission therapy for 24 weeks.
Study: NCT01268995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Patients randomized into arm A will be switched from Tacrolimus to Cyclosporine A. Conversion will be done by a stop and go protocol. Patients will take their last dose Tacrolimus in the morning of the day of conversion and will start taking Cyclosporine A in the evening of the same day at a dose of 3mg/kg/d. The first measurement of Cyclosporine A trough levels will be performed 3 days after conversion and the dose will then be adjusted if necessary. Furthermore, treatment with NPH insulin once daily in the morning will be initiated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Patients in arm B will remain on their immunosuppressive therapy with Tacrolimus. Furthermore, treatment with NPH insulin once daily in the morning will be initiated.
Study: NCT04400266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Buspirone 15mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mealatonin
Description: Melatonin 3mg once nightly
Study: NCT01689597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Comparison of different dosages of drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Comparison of different dosages of drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03456245

Intervention type: DEVICE
Intervention: Vision device validation
Description: Group members had their vision tested with the following devices/methods: Eyenetra NETRA, PlenOptika Quicksee, Right Manufacturing Retinomax K Plus 3, and standard eyesight tests using eye charts, phoropters, and slit lens lamp imaging.
Study: NCT04078009

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Aquagen
Description: To compare the clinical allergic response after direct installation of an aqueous solution of Aquagen Timothy Grass pollen extract via nasal allergen challenge with the clinical allergic response after direct installation of an aqueous solution of Grazax Timothy Grass lyophilisate tablets via nasal allergen challenge in grass pollen allergic individuals.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Grazax
Description: To compare the clinical allergic response after direct installation of an aqueous solution of Aquagen Timothy Grass pollen extract via nasal allergen challenge with the clinical allergic response after direct installation of an aqueous solution of Grazax Timothy Grass lyophilisate tablets via nasal allergen challenge in grass pollen allergic individuals.
Study: NCT02354768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Effects of lanreotide with current anti-diarrheal treatments (diosmectite and loperamide)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effects of current anti-diarrheal treatments (diosmectite and loperamide) alone